Intellia Therapeutics (NASDAQ: NTLA) reported Q3 EPS of ($1.34), $0.05 better than the analyst estimate of ($1.39). Revenue for the quarter came in at $9.11 million versus the consensus estimate of $8.28 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.